These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6178950)

  • 1. Unlearning about latency.
    Koprowski H
    Med Microbiol Immunol; 1982; 170(4):209-19. PubMed ID: 6178950
    [No Abstract]   [Full Text] [Related]  

  • 2. An inquiry into the mechanisms of herpes simplex virus latency.
    Roizman B; Sears AE
    Annu Rev Microbiol; 1987; 41():543-71. PubMed ID: 2825588
    [No Abstract]   [Full Text] [Related]  

  • 3. Membrane and cytoplasmic changes in virus-infected cells induced by interactions of antiviral antibody with surface viral antigen.
    Oldstone MB; Fujinami RS; Lampert PW
    Prog Med Virol; 1980; 26():45-93. PubMed ID: 6158744
    [No Abstract]   [Full Text] [Related]  

  • 4. Latency of herpes simplex virus in absence of neutralizing antibody: model for reactivation.
    Sekizawa T; Openshaw H; Wohlenberg C; Notkins AL
    Science; 1980 Nov; 210(4473):1026-8. PubMed ID: 6254149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Problems of herpes simplex virus latency.
    Klein RJ
    Antiviral Res; 1985; Suppl 1():111-20. PubMed ID: 3002250
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of Fc receptors in herpes simplex virus infection.
    Costa JC; Rabson AS
    Lancet; 1975 Jan; 1(7898):77-8. PubMed ID: 46027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latent infection by herpes simplex virus.
    Costa JC; Rabson AS
    Pathol Annu; 1979; 14 Pt 2():61-8. PubMed ID: 232755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigens of herpes simplex virus of oral and genital origin.
    Wildy P
    Cancer Res; 1973 Jun; 33(6):1465-8. PubMed ID: 4124113
    [No Abstract]   [Full Text] [Related]  

  • 9. Latent herpes simplex virus and the nervous system,
    Stevens JG
    Curr Top Microbiol Immunol; 1975; 70():31-50. PubMed ID: 169103
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative concentrations in human sera of antibodies to cross-reacting and specific antigens of Herpes simplex virus types 1 and 2.
    McClung H; Seth P; Rawls WE
    Am J Epidemiol; 1976 Aug; 104(2):192-201. PubMed ID: 60058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene "anti-sense" transcript by in situ hybridization.
    Croen KD; Ostrove JM; Dragovic LJ; Smialek JE; Straus SE
    N Engl J Med; 1987 Dec; 317(23):1427-32. PubMed ID: 2825014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiments and speculation on antiviral specificity of T and B cells.
    Zinkernagel RM; Rosenthal KL
    Immunol Rev; 1981; 58():131-55. PubMed ID: 6171502
    [No Abstract]   [Full Text] [Related]  

  • 13. The pathogenesis of acute, latent and recurrent herpes simplex virus infections.
    Klein RJ
    Arch Virol; 1982; 72(3):143-68. PubMed ID: 6180702
    [No Abstract]   [Full Text] [Related]  

  • 14. Virus-related pathology: is the continued presence of the virus necessary?
    Huppert J; Wild TF
    Adv Virus Res; 1986; 31():357-85. PubMed ID: 2428215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes simplex virus infection in sensory ganglia: immune control, latency, and reactivation.
    Openshaw H; Puga A; Notkins AL
    Fed Proc; 1979 Dec; 38(13):2660-4. PubMed ID: 228982
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunological basis for latency, recurrences and putative oncogenicity of herpes simplex virus.
    Lehner T; Wilton JM; Shillitoe EJ
    Lancet; 1975 Jul; 2(7924):60-2. PubMed ID: 49654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The continuing problem of herpes simplex virus persistence.
    Rajcáni J; Szántó J
    Acta Virol; 1983 Sep; 27(5):442-50. PubMed ID: 6139950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the virulence genes of herpes simplex virus 2 by experimental infection in vivo with defined intertypic recombinants of a virulent HSV-2 X an avirulent HSV-1.
    Rösen A; Darai G
    Med Microbiol Immunol; 1985; 174(5):237-48. PubMed ID: 3003551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation.
    Openshaw H; Asher LV; Wohlenberg C; Sekizawa T; Notkins AL
    J Gen Virol; 1979 Jul; 44(1):205-15. PubMed ID: 227991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.